Post-Marketing Surveillance of Polatuzumab Vedotin: A Disproportionality Analysis of the US FDA Adverse Event Reporting System (FAERS) Database

被引：0
|
作者：
Muscara, Claudia [1 ]
Allegra, Alessandro [2 ]
Tuccoli, Marco [3 ]
Flaccavento, Alessandra [4 ]
Cutroneo, Paola Maria [1 ]
机构：
[1] Univ Hosp Messina, Sicilian Reg Pharmacovigilance Ctr, Clin Pharmacol Unit, Messina, Italy
[2] Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano B, Hematol Unit, Messina, Italy
[3] Univ Hosp Pisa, Unit Adverse Drug React Monitoring, Pisa, Italy
[4] Univ Pisa, Dept Clin & Expt Med Sect Pharmacol & Pharmacovig, Pisa, Italy
来源：
DRUG SAFETY | 2024年 / 47卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
210
引用
收藏
页码：1408 / 1408
页数：1
相关论文
共 50 条
  • [41] Post-marketing safety of Adagrasib: a disproportionality analysis based on the FAERS database
    Shi, Zheng
    Yu, Xiayao
    Zhao, Yifan
    Shao, Keda
    Xu, Chunwei
    Song, Zhengbo
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [42] Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
    Xiong, Rui
    Lei, Jing
    Pan, Sicen
    Zhang, Hong
    Tong, Yongtao
    Wu, Wei
    Huang, Yi
    Lai, Xiaodan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [43] A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
    Xue, Zehu
    Liu, Xi
    Liu, Qifeng
    Yang, Xiuming
    Yu, Lixia
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [44] Comparing Common Therapies in Polycythemia Vera (PV): A Disproportionality Analysis in the FDA Adverse Event Reporting System (FAERS) Database
    Snopek, Frank
    Seddighzadeh, Ali
    Flynn, Megan
    Cai, Ling-Yu
    Chen, Esther
    Shih, Weichung Joe
    Qin, Albert
    Urbanski, Raymond W.
    BLOOD, 2023, 142
  • [45] A Disproportionality Analysis of Treprostinil Based on FDA Adverse Event Reporting System Database
    Li, Lingling
    Song, Weiqiang
    Jiao, Wanli
    ANNALS OF PHARMACOTHERAPY, 2024,
  • [46] Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database
    Jiang, Tingting
    Li, Yanping
    Zhang, Ni
    Gan, Lanlan
    Su, Hui
    Xiang, Guiyuan
    Wu, Yuanlin
    Liu, Yao
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2025, 16
  • [47] A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
    Tian, Yalan
    Jin, Min
    Ning, Hong
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [48] Post-Marketing Safety of Anti-Calcitonin Gene Related Peptide Antibodies: A Disproportionality Analysis of the FDA Adverse Event Reporting System
    Giunchi, V.
    Fusaroli, M.
    Antonazzo, I. C.
    Hyeraci, G.
    Raschi, E.
    Poluzzi, E.
    Mazzaglia, G.
    Roberto, G.
    DRUG SAFETY, 2022, 45 (10) : 1245 - 1245
  • [49] Association of sacubitril/valsartan with hypoacusis unveiled through disproportionality analysis in US FDA adverse event reporting system (FAERS)
    Chiranjeevi, Pudi
    Saraswathy, G. R.
    Viswam, Subeesh Kulangara
    Swaroop, Ann Mary
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 131 - 131
  • [50] Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-Peng
    Yang, Hai-Yun
    Ouyang, Mengling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-Hui
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (03) : 353 - 362
12345